Clinical Trial Update: An Imaging Study to Investigate the Distribution of GSK239512 in the Brain. [Phase 1]

View source ↗

Summary

Phase 1 imaging study to evaluate how the experimental brain-penetrant drug GSK239512 distributes in the brain in individuals with mild cognitive impairment or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Dementia

Drugs mentioned

• GSK239512 (GSK239512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Mild Cognitive Impairment, Dementia | Phase 1 | Status: COMPLETED